Cencora, Inc. COR
Healthcare · Medical Distribution · United States · S&P 500
Based on the available data, Cencora, Inc. gets an algorithmic score of 45/100. It trades at 307.60 $, with a sideways/transition technical trend (RSI 41.7) and 30.9% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (96.9%): generates strong profit on equity.
- Sustained revenue growth (10.4% compound annual).
- Attractive free-cash-flow yield (5.5%).
- Low beta (-0.03): defensive profile.
- Meaningful dividend (78.00%).
Weaknesses
- Thin net margin (0.8%): vulnerable to costs.
- High leverage (debt/equity 447%): rate-sensitive.
Fundamentals
| P/E | 22.84 |
| Forward P/E | 15.51 |
| PEG | 0.65 |
| P/B | 19.24 |
| EV/EBITDA | 12.72 |
| P/S | 0.18 |
| ROE % | 96.87 |
| ROA % | 3.56 |
| Gross margin % | 3.96 |
| Operating margin % | 1.41 |
| Net margin % | 0.79 |
| Revenue growth % (y/y) | 5.10 |
| Earnings growth % (y/y) | 11.90 |
| Revenue CAGR % | 10.43 |
| Earnings CAGR % | -2.92 |
| Debt/Equity % | 446.52 |
| Current ratio | 0.94 |
| FCF yield % | 5.46 |
| Dividend yield % | 78.00 |
| Payout % | 17.45 |
Returns
| 1 month | -4.5 % |
| 3 months | +8.9 % |
| 6 months | -0.3 % |
| YTD | -8.7 % |
| 1 year | +1.0 % |
| 3 years | +69.6 % |
| 5 years | +171.9 % |
Risk
| 1-year volatility | 30.9 % |
| Beta | -0.03 |
| 5-year max drawdown | -32.4 % |
| Sharpe 1A | 0.06 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.